Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of dovitinib in advanced urothelial carcinoma with mutant or wild-type FGFR3
2008-005870-11Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dovitinib in transitional cell carcinoma (TCC) (2 cohorts), sponsored by Novartis. Primary endpoints: Overall response rate and Overall response rate by central assessment. Started Dec 2009; status: completed.
02
Drugs
dovitinib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2008-005870-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005870-11.